Blog
Johnson & Johnson applies for preliminary approval of nipocalimab to deal with as many individuals as attainable with antibody-positive generalized myasthenia gravis
24
Sep
Sep
Johnson & Johnson right now introduced that it has submitted a Biologics License Software (BLA) to the U.S. Meals and Drug Administration (FDA) looking for the world’s first approval of nipocalimab to deal with individuals with generalized myasthenia gravis (gMG). The applying included knowledge from the Section 3 Vivacity-MG3 trial, which confirmed that outcomes have […]